Basaglar

Insulin Glargine

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Basaglar

Quick Facts

Property	Description
Active ingredient	Insulin Glargine
Form	Sterile solution for injection (pre-filled pen)
Pharmacological class	Long-acting basal insulin; Antidiabetic drug
Common use	Basal (background) blood sugar control
Origin	Synthetic, recombinant human insulin analogue

Basaglar: Definition and Pharmacological Classification

Basaglar is the trade name for a prescription-only antidiabetic drug whose active ingredient is Insulin Glargine. It is specifically classified as a long-acting basal insulin functioning as a necessary replacement therapy to provide continuous, background insulin levels. It is recognized as a biosimilar to the reference Insulin Glargine product, a status supported by pharmacological studies confirming its functional equivalence and clinical effectiveness.

This medication belongs to the broader class of endocrine system agents and is vital for individuals whose bodies cannot produce sufficient or effective basal insulin. Its role is distinguished because it focuses on maintaining the stable, foundational glucose-lowering control required outside of mealtimes.

Composition, Origin, and Action Profile

The core component, Insulin Glargine, is a synthetic human insulin analogue produced through recombinant DNA technology. This manufacturing process creates a structurally modified protein molecule that is highly similar in function to human insulin. Basaglar is supplied as a clear, sterile solution designed for subcutaneous injection using a pre-filled pen device.

Its formulation facilitates a controlled, sustained release over approximately 24 hours. The clinical goal of this consistent, peakless action is to minimize variability in insulin concentration, thereby supporting predictable blood sugar control across the entire day-and-night cycle.

General Purpose of Basal Insulin Replacement

The general purpose of Basaglar is to provide reliable, stable blood sugar control by supplying the necessary background insulin activity. By ensuring continuous basal insulin action, the drug supports the body’s overall energy regulation and metabolic baseline. Its typical use involves a once-daily administration to prevent blood sugar from rising excessively during prolonged periods, such as when a patient is fasting or sleeping.

What side effects are possible with Basaglar ?

Adverse Reactions and Safety Information

Basaglar (insulin glargine) is associated with documented side effects and serious safety warnings based on governmental regulatory documents.

Key Adverse Reactions

The most frequent adverse reaction is Hypoglycemia (low blood sugar), classified as Very Common (1/10 incidence) and is a risk with all insulins. Other common (1/100 to <1/10) reactions include Injection Site Reactions (such as pain, redness, or swelling), Lipodystrophy (skin thickening or pitting at the injection site), and Weight Gain.

Adverse Reaction Category	Frequency Classification
Hypoglycemia (Low Blood Sugar)	Very Common
Injection Site Reactions	Common
Lipohypertrophy, Edema (Fluid Retention), Rash, Weight Gain	Common / Adverse Reaction
Severe Allergic Reactions (Anaphylaxis), Hypokalemia	Rare / Serious

Serious and Clinically Significant Safety Information

Serious Adverse Reactions include severe, life-threatening Hypoglycemia, which can lead to seizures, coma, or death. Severe Systemic Allergic Reactions (hypersensitivity, including anaphylaxis) and potentially life-threatening Hypokalemia (low potassium in the blood) are also noted. Fluid retention and risk of new or worsening Heart Failure may occur when Basaglar is used concurrently with thiazolidinediones (TZDs).

Safety Restrictions and Limitations

Basaglar is contraindicated during episodes of hypoglycemia and in patients with a history of hypersensitivity to insulin glargine or any of its excipients. Proper technique is mandatory: injection sites must be rotated within the same area to minimize the risk of lipodystrophy or cutaneous amyloidosis, which can affect insulin absorption. Regulatory documents strictly caution against sharing the injection pen between patients to prevent the transmission of blood-borne pathogens. Monitoring of blood glucose, potassium levels, and cardiac status (if taking TZDs) is explicitly required.

Connection to the Overall Safety Profile

The official safety information highlights that the primary and most frequent risk is dose-dependent hypoglycemia, underscoring the need for careful glucose monitoring. The profile also defines rare but severe systemic risks, such as anaphylaxis and hypokalemia, and a specific clinical restriction concerning co-administration with TZDs due to the associated risk of heart failure. The overall structure mandates that safety protocols focus on monitoring, proper injection site rotation, and strict adherence to non-sharing protocols.

Overdose and Emergency Response

The sole clinical manifestation of a Basaglar (Insulin Glargine) overdose is a state of hypoglycemia, which can range from mild to life-threatening. Officially documented symptoms are divided into adrenergic effects, such as tremor, diaphoresis (sweating), palpitations, and anxiety, and neuroglycopenic effects, including confusion and lethargy. The primary laboratory finding is a low blood glucose concentration, which may be accompanied by hypokalemia.

When Immediate Medical Help is Required

Emergency medical care is required immediately if the symptoms escalate to severe hypoglycemia, marked by seizures or loss of consciousness. Due to the sustained action of Basaglar, severe or sustained episodes carry the risk of irreversible neurological impairment, making prompt treatment essential. Seek immediate medical attention or contact emergency services in these severe situations.

Documented Management and Monitoring

Management is focused on correcting the low blood glucose level. Mild hypoglycemia is managed through the administration of oral glucose or fast-acting carbohydrates. Severe episodes require the administration of intravenous glucose solution or parenteral glucagon. Following intervention, frequent blood glucose monitoring is required. Regulators note that patients with pre-existing renal or hepatic impairment may be at an increased risk of prolonged hypoglycemia, necessitating closer and extended observation, often requiring hospitalization for continuous monitoring.

Therapeutic Uses of Basaglar

What Basaglar Treats: Main Uses and Benefits

Basaglar may assist with glycemic control in adult and pediatric patients with Type 1 diabetes mellitus, and in adults with Type 2 diabetes mellitus. This therapeutic function is applied in scenarios requiring foundational glucose management and is not used for addressing acute, rapid-onset conditions like diabetic ketoacidosis.

This medication is applied as long-term basal insulin callout replacement therapy in chronic situations where the body cannot produce sufficient continuous, background insulin. It is relevant for easing symptoms related to systemic imbalance, specifically addressing the symptom cluster of persistent high fasting glucose and nocturnal hyperglycemia across the 24-hour cycle.

This medication plays a role in managing a baseline metabolic rate when the patient is not actively eating, supporting functional stability throughout the day and night.

In clinical scenarios, Basaglar is commonly used within a comprehensive treatment plan. For Type 1 diabetes, it helps with providing the necessary background insulin activity that works alongside mealtime (bolus) insulin; for Type 2 diabetes, it is often introduced when other oral medications have been insufficient to achieve stable goals. Its role contributes to easing the overall symptom load related to chronic hyperglycemia, which supports general well-being during symptomatic phases.

Quick Fact: Relief for Fasting and Nocturnal High Glucose

Therapeutic Focus	Benefit
Symptom Cluster	Persistent high fasting glucose, nocturnal hyperglycemia
Clinical Context	Long-term basal insulin replacement therapy
Primary Benefit	Supports maintenance of functional stability and contributes to easing the symptom load related to systemic imbalance
Patient Groups	Adults (T1D & T2D), Pediatric patients (T1D, age 6+)

Eligibility and Restrictions for Use

Basaglar eligibility is strictly defined by regulatory authorities regarding who can and cannot use the medicine.

Absolute Contraindications

Basaglar is contraindicated and must not be used during documented episodes of hypoglycemia (low blood sugar). It is also prohibited for patients with a known hypersensitivity to insulin glargine or any of its excipients. The medicine is not recommended for the treatment of Diabetic Ketoacidosis (DKA), as it is intended only for basal glucose control.

Age-Group and Indication Eligibility

Target Population	Eligibility Status
Adults (T1D & T2D)	Approved for use.
Pediatric (T1D)	Approved for patients 6 years of age and older.
Pediatric (T2D)	Not indicated (use is not established).
Children < 6 years (T1D)	Safety and efficacy not established.

Condition-Specific Restrictions

Use requires caution and close monitoring in patients with renal impairment or hepatic impairment. These conditions may lead to a decrease in insulin requirements, necessitating special management. Caution is also advised for patients at risk of hypokalemia (low potassium). Use during pregnancy is permitted only if the potential benefit outweighs the potential risk to the fetus, but it is generally considered acceptable during lactation.

What should I know about interactions with other medicines?

The interaction profile of Basaglar (Insulin Glargine) is primarily defined by documented changes to its glucose-lowering effect, which are categorized by the regulatory authorities.

Official Pharmacodynamic Interactions

Interaction Type	Examples of Documented Agents	Regulatory Outcome
Increased Risk of Hypoglycemia	Other antidiabetic agents, Angiotensin-Converting Enzyme (ACE) Inhibitors, Salicylates, MAOIs, Sulfonamide antibiotics, Fibrates, Fluoxetine, Alcohol	Potentiation of glucose-lowering action
Decreased Glucose-Lowering Effect	Corticosteroids, Diuretics, Thyroid hormone replacements, Growth Hormone, Estrogens, Niacin, Atypical antipsychotics, Sympathomimetic agents	Antagonism of glucose-lowering action
Masking of Hypoglycemia Symptoms	Beta-blockers, Clonidine, Reserpine	Blunting of sympathetic awareness signs

Co-administration with alcohol (ethanol) is officially documented to have a variable effect, potentially potentiating or diminishing the blood glucose-lowering action. Additionally, the regulatory information highlights that use with Thiazolidinediones (TZDs) carries an increased risk of dose-related fluid retention and the onset or worsening of heart failure.

Administration and Population-Specific Constraints

The prescribing information mandates strict procedural restrictions: Basaglar must not be diluted or mixed with any other insulin or solution, as this can unpredictably alter the sustained-release profile. For patients with renal or hepatic impairment, official labeling indicates that increased frequency of glucose monitoring is required due to potentially reduced insulin metabolism.

Mechanism of Action

Basaglar (insulin glargine) is a long-acting insulin analog that functions with sustained receptor-binding affinity. Its mechanism of action is mediated through binding to insulin receptors (IRs) expressed on the surface of target cells, primarily muscle and adipose tissue. This receptor engagement initiates an intracellular cascade that facilitates the translocation of glucose transporters, thereby mediating the cellular uptake of glucose for utilization or storage.

Upon subcutaneous injection, Basaglar's acidic formulation leads to the formation of stable microprecipitates in the neutral subcutaneous environment. The controlled, slow dissolution of these precipitates results in a flat concentration-time profile, generating a steady 24-hour basal insulin profile with consistent insulin receptor engagement.

Furthermore, the activated insulin signaling cascade acts upon the liver to suppress key enzymes involved in gluconeogenesis (glucose synthesis) and glycogenolysis (glycogen breakdown). By inhibiting these processes, the mechanism modulates circulating glucose concentrations by reducing hepatic glucose output.

Dosage and Administration Information

Administration Overview

Basaglar is a long-acting insulin glargine administered via subcutaneous injection. This means it is injected into the fatty tissue just beneath the skin. Common injection sites include the abdomen, the upper arms, or the thighs. It is important to rotate the injection site within the chosen area for every dose to reduce the risk of developing fatty lumps or skin thickening at the site of injection.

Consistency in Use

For optimal blood sugar management, the injection is typically administered once daily. Maintaining a consistent schedule by injecting the medication at the same time each day helps ensure a steady level of insulin in the bloodstream.

Handling and Preparation

The medication should be inspected before use; it should appear clear and colorless. If the solution is cloudy, colored, or contains visible particles, it should not be used.

If using a delivery device such as a prefilled pen, a new sterile needle must be attached for every injection. It is essential that delivery devices and needles are never shared between individuals, even if the needle has been changed, to prevent the transmission of blood-borne pathogens.

Storage and Delivery Systems

Basaglar is available in different delivery formats, such as prefilled pens. Each format requires specific handling according to its design. The medication should not be mixed with any other insulin products or diluted, as this can change its onset and duration of action. After the injection is complete, the needle should be removed and disposed of in a puncture-resistant sharps container.

Recent Clinical Evidence

Basaglar: Recent Clinical Evidence

Basaglar is an insulin glargine injection approved to improve blood sugar control in adults with type 1 or type 2 diabetes and in pediatric patients (ages six and older) with type 1 diabetes.

Clinical Efficacy and Equivalence

The clinical development program for Basaglar included Phase 3 studies that compared its effects on blood sugar control, specifically HbA1c levels, against its reference product, Lantus. The results of these trials showed that Basaglar provided glycemic control that was similar in efficacy to the reference product in both type 1 and type 2 diabetes patients.

Type 1 Diabetes (ELEMENT 1): In a 52-week trial in adults with Type 1 diabetes, Basaglar, used with mealtime insulin, was found to have a similar effect on the reduction of HbA1c from baseline compared to the reference product.
Type 2 Diabetes (ELEMENT 2): In a 24-week trial in adults with Type 2 diabetes receiving oral anti-diabetic medications, the reduction in HbA1c levels from baseline was similar for both Basaglar and the reference product.

Safety and Tolerability Findings

Studies focused on ensuring a comparable safety profile. The trials examined adverse events, rates of hypoglycemia (low blood sugar), and immunogenicity (the development of anti-insulin antibodies).

Safety Measure	Study Finding (Compared to Reference Product)
Overall Adverse Events	The incidence of treatment-emergent adverse events was similar.
Hypoglycemia Rates	No significant differences were observed in the rates of total or nocturnal hypoglycemia.
Insulin Antibody Development	The frequency and level of anti-insulin antibodies were found to be generally comparable.

In both Type 1 and Type 2 diabetes trials, weight gain was commonly observed, which is a known side effect associated with all insulin therapies.

Frequently Asked Questions (FAQ)

Common questions about Basaglar (FAQ)

Q: How is Basaglar different from Lantus?

Official information describes Basaglar as a biosimilar product to Lantus, the reference product. This means that Basaglar is highly similar to Lantus and shows no clinically meaningful differences from it in terms of safety and effectiveness. Both medicines contain the same active ingredient, insulin glargine, and are used to help control blood sugar.

Q: Can Basaglar be taken at the same time as other medications?

Basaglar is administered as a subcutaneous injection once daily at the same time each day, independent of meal timing. Regulatory documents strictly state that Basaglar must never be mixed or diluted with any other insulin or liquid. Guidance on taking it with other medications should be reviewed with a healthcare provider.

Q: Is Basaglar safe for use during pregnancy?

Regarding use during pregnancy, official product information states that it is permitted only if a healthcare provider determines that the potential benefit to the patient justifies the potential risk to the fetus. The decision for use during pregnancy is based on a risk assessment by a qualified medical professional.

Q: Can the Basaglar pen be reused?

The Basaglar KwikPen is a pre-filled pen device designed for multi-dose use by a single person. Once the pen is first used, it can be kept at room temperature and is stable for 28 days, after which it must be discarded, even if insulin remains. Regulatory safety information advises against sharing the pen with any other person to avoid the potential transmission of blood-borne pathogens.

Q: Is Basaglar intended to be the only medication for diabetes?

Basaglar is classified as a basal (background) insulin, meaning its purpose is to provide continuous, stable blood sugar control outside of mealtimes. For patients with Type 1 diabetes, the official dosing instructions state it must be used in conjunction with a rapid-acting, mealtime insulin. In other cases, it may be used alongside oral diabetes medications or other injectable therapies, as determined by a healthcare provider.

Q: Does the body develop resistance to Basaglar over time?

During clinical trials, researchers monitored for the development of anti-insulin antibodies, which are sometimes associated with the body’s reaction to insulin products. Studies found that the frequency and levels of these antibodies for Basaglar were generally comparable to those seen with the reference insulin product.

Q: How quickly does Basaglar start working?

The medication is formulated to work over a sustained period rather than quickly. After injection, its acidic solution forms microprecipitates in the skin, which dissolve slowly to create a steady, peakless insulin profile. This slow dissolution is what allows the insulin to last for approximately 24 hours.

Q: Are there specific vitamins or supplements that interact with Basaglar?

Regulatory documents list interactions with many classes of prescription and non-prescription medications that can change blood sugar levels. Official guidance emphasizes that patients should inform their healthcare provider about all substances they take, including vitamins, herbal supplements, and over-the-counter products, as these may impact how Basaglar works.

Q: Is it normal to feel a stinging sensation when injecting Basaglar?

Injection Site Reactions, such as pain, swelling, or redness at the site, are noted as a Common side effect (1/100 to <1/10) in official documents. The product's formulation may be a contributing factor to the stinging sensation sometimes reported during injection.

Q: What does 'biosimilar' mean in relation to Basaglar?

A biosimilar is a biological product, such as insulin, that is highly similar to, and has no clinically meaningful differences from, an existing FDA-approved reference product. Biosimilars are different from generic drugs, which are chemically identical copies of small-molecule drugs. The designation means Basaglar has been approved based on evidence demonstrating comparable safety and effectiveness.

Q: Are there any long-term effects of using Basaglar?

Clinical trials for Basaglar studied patients for up to 52 weeks and did not identify any new or unexpected safety concerns. Regulatory documents outline known risks associated with long-term insulin use, such as weight gain and changes in the skin at the injection site (lipodystrophy), which are common adverse reactions.

Q: Does Basaglar have a high risk of drug interactions?

The official product information contains extensive sections detailing numerous types of medications that can change the way Basaglar affects blood sugar. Interactions are categorized by whether they may increase (e.g., certain blood pressure or antibiotic medications) or decrease (e.g., corticosteroids or growth hormone) the glucose-lowering effect of Basaglar.

Q: Is there a version of Basaglar that is not a pen?

According to official regulatory documents regarding dosage forms, Basaglar is supplied solely as a solution for injection in the pre-filled pen device known as the KwikPen. Other formats, such as vials, are not listed in the product information.

Q: Does taking Basaglar impact driving ability?

Since Basaglar can cause hypoglycemia (low blood sugar), which is the most frequent adverse reaction, it may impair a person's ability to concentrate and react quickly. Official safety information notes that due to this risk, patients should be aware of the need for precautions when driving or operating machinery.

Q: What are the warning signs associated with Basaglar use?

The most serious documented safety concerns include severe, life-threatening low blood sugar and severe allergic reactions. Warning signs associated with these serious adverse reactions include symptoms of severe hypoglycemia (such as confusion, seizures, or passing out) and severe systemic allergic reactions (such as throat swelling or difficulty breathing).

Q: Are there any known interactions between Basaglar and common pain relievers?

Regulatory documents specifically list Salicylates as a class of medication that may interact with Basaglar. Salicylates, which include aspirin, are documented as agents that can increase the risk of hypoglycemia (low blood sugar) when used alongside Basaglar.

Q: Does Basaglar require special injection training?

Official patient instructions and package leaflets recommend that patients receive proper instruction on how to use the Basaglar pen. This instruction covers techniques such as proper handling and injection site rotation to support correct administration and absorption.

Q: What should I know about switching to Basaglar from another insulin?

If transitioning to Basaglar from another type of insulin, official product information indicates that close metabolic monitoring (blood glucose testing) is required. Additionally, the change may necessitate an adjustment in the dose of both your basal (background) insulin and any mealtime insulin you use.

Q: Is Basaglar used to treat a condition other than diabetes?

According to official therapeutic indications, Basaglar is only approved for the improvement of blood sugar control in adults and eligible pediatric patients with diabetes mellitus (Type 1 or Type 2).

Q: What is the difference between a biosimilar and a generic drug?

A biosimilar is a highly similar version of a biologic medicine, like insulin, which is made from living sources. A generic drug, by contrast, is a chemically identical copy of a small-molecule drug. Basaglar is considered a biosimilar, meaning it is similar to the reference biological product with no clinically meaningful differences.

How should Basaglar be stored and disposed of?

How to Store and Dispose of Basaglar

Proper storage and handling are essential for maintaining the effectiveness of Basaglar (insulin glargine).

Unopened Pens

Unused Basaglar KwikPens must be stored in a refrigerator at a temperature between 2 C and 8 C (36 F and 46 F). Pens must be protected from light and kept in their original sealed carton until ready for use.

In-Use Pens

Once a Basaglar KwikPen is first used, it should be stored at room temperature, but kept below 30 C (86 F). The pen is stable for a period of 28 days after first use. After this 28-day period, the pen must be discarded, even if it still contains insulin.

Key Requirements